| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
THERAPEUTIC REVIEW |
From the Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts–New England Medical Center, Boston, Massachusetts.
Variability in the anticoagulant response to warfarin is an ongoing clinical dilemma. Fluctuations in dietary vitamin K are an important source of variance, and the need for constancy in vitamin K intake is routinely emphasized for warfarin-treated patients. Anticoagulant response is also influenced by a number of drugs that induce or inhibit warfarin metabolism, as well as by genetic polymorphisms that may modulate expression or activity of CYP2C9, the isoform mediating clearance of S-warfarin. The possible role of dietary factors other than vitamin K, as well as of herbal medicines or supplements as contributors to the instability of anticoagulation in warfarin-treated patients, has received recent attention. St. John's wort and possibly some ginseng formulations may have the potential to diminish warfarin anticoagulation, apparently by inducing CYP2C9 activity. Otherwise, there is no reliable evidence to indicate that any dietary component (other than vitamin K) or any herbal product has an effect on the anticoagulant response to warfarin. Scientific conclusions on this important therapeutic issue should be based on valid scientific data rather than unvalidated case reports.
Key Words: Warfarin • drug interactions • food interactions • herbal interactions
Address for reprints: David J. Greenblatt, MD, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111.
This article has been cited by other articles:
|
|
 |
|
  E. Sjodin, H. Fritsch, U. G. Eriksson, U. Logren, A. Nordgren, P. Forsell, L. Knutson, and H. Lennernas Intestinal and Hepatobiliary Transport of Ximelagatran and Its Metabolites in Pigs Drug Metab. Dispos., August 1, 2008; 36(8): 1519 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Juurlink MD PhD Drug interactions with warfarin: what clinicians need to know Can. Med. Assoc. J., August 14, 2007; 177(4): 369 - 371. [Full Text] [PDF]
|
|
|
|
 |
|
 R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Oberwittler, A. Hirschfeld-Warneken, R. Wesch, H. Willerich, L. Teichert, K.-H. Lehr, R. Ding, W. E. Haefeli, and G. Mikus Significant Pharmacokinetic and Pharmacodynamic Interaction of Warfarin With the NO-Independent sGC Activator HMR1766 J. Clin. Pharmacol., January 1, 2007; 47(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jiang, E. Y. L. Blair, and A. J. McLachlan Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J. Clin. Pharmacol., November 1, 2006; 46(11): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Feldstein, D. H. Smith, N. Perrin, X. Yang, S. R. Simon, M. Krall, D. F. Sittig, D. Ditmer, R. Platt, and S. B. Soumerai Reducing warfarin medication interactions: an interrupted time series evaluation. Arch Intern Med, May 8, 2006; 166(9): 1009 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Greenblatt, R. A. Leigh-Pemberton, and L. L. von Moltke In Vitro Interactions of Water-Soluble Garlic Components with Human Cytochromes P450 J. Nutr., March 1, 2006; 136(3): 806S - 809S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Greenblatt, L. L. von Moltke, Y. Luo, E. S. Perloff, K. A. Horan, A. Bruce, R. C. Reynolds, J. S. Harmatz, B. Avula, I. A. Khan, et al. Ginkgo biloba Does Not Alter Clearance of Flurbiprofen, a Cytochrome P450-2C9 Substrate J. Clin. Pharmacol., February 1, 2006; 46(2): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
